Episode

Axiom’s Hong Kong Bet, Latigo’s Positive Phase II, and Base Editors for Huntington’s

Podcast
Touching Base
Published
Jul 31, 2026
Duration seconds
1936
Processing state
not_requested
Canonical source
https://shows.acast.com/touching-base/episodes/axioms-hong-kong-bet-latigos-positive-phase-ii-and-base-edit
Audio
https://sphinx.acast.com/p/open/s/65736d39d32e730012c98919/e/6a6ca91388c5585c85e9e684/media.mp3
JSON
/v1/public/podcasts/touching-base-6714887/episodes/axiom-s-hong-kong-bet-latigo-s-positive-phase-ii-and-base-editors-for-huntington-s
Markdown
/podcast/touching-base-6714887/axiom-s-hong-kong-bet-latigo-s-positive-phase-ii-and-base-editors-for-huntington-s.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/touching-base-6714887/episodes/axiom-s-hong-kong-bet-latigo-s-positive-phase-ii-and-base-editors-for-huntington-s/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/touching-base-6714887/axiom-s-hong-kong-bet-latigo-s-positive-phase-ii-and-base-editors-for-huntington-s.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In the business news section of this week’s episode, Axiom Biosciences recently announced its plans to go public and made headlines for its plans to do so on the Hong Kong Exchange rather than a U.S. market. We dig into the company’s reasoning. Then we turn our attention to Latigo’s report of positive Phase IIb data for its non-opioid acute pain candidate, and its plans to go through a planned IPO soon. Switching to some science news, we discuss findings from a study that identified genetic risk factors for fibromyalgia syndrome as well as links to other neurodegenerative, autoimmune, and metabolic diseases. And lastly, a potential base editing therapy for Huntington’s disease that has shown promise in mice. Join GEN editors Corinna Singleman, PhD, Alex Philippidis, and Uduak Thomas for a discussion of the latest biotech and biopharma news.  Listed below are links to the GEN stories referenced in this episode of Touching Base : StockWatch: Axiom CEO Explains Plans for Hong Kong IPO  By Alex Philippidis, GEN Edge , July 27, 2026 Latigo Reports Positive Phase IIb Data for Non-Opioid Acute Pain Candidate By Alex Philippidis, GEN Edge , July 30, 2026 Genetic Study of Fibromyalgia Points to Neurological Basis  GEN , July 29, 2026 Base Editing Strategy Alleviates Huntington’s Disease in Mice  GEN , July 29, 2026 Touching Base Podcast Hosted by Corinna Singleman, PhD Behind the Breakthroughs Hosted by Jonathan D. Grinstein, PhD The State of Biologics Testing 2026 Charles River Laboratories and GEN , June 10, 2026 Hosted on Acast. See acast.com/privacy for more information.